Semaglutide vs Tirzepatide: How the Two Actually Differ

Two medications, one drug family, and a great deal of confident advice online about which is better. They do differ in a specific, mechanistic way — and that difference shows up in the data. It is still not the only thing that should decide which one you are prescribed, or whether either is appropriate for you at all.

Both drugs arrived in obesity medicine from diabetes care, and both are prescription medications that require a clinical evaluation before anyone can say whether they are suitable. If you want the wider picture of how this class works and what the evidence base looks like, start with our complete guide to GLP-1 medications for weight management. This article is narrower: how these two specific molecules differ, and what actually drives the choice between them in practice.

What each drug is

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after you eat. It slows the rate at which the stomach empties, prompts insulin release when glucose is high, suppresses glucagon, and acts on appetite-regulating regions of the brain. Semaglutide is a modified version of that hormone, engineered to resist the enzyme that would normally break it down within minutes, which is why it can be injected once a week rather than continuously.

Tirzepatide does the same thing at the GLP-1 receptor and also activates the receptor for GIP — glucose-dependent insulinotropic polypeptide, another gut hormone released after eating. Hence "dual agonist". GIP's role in appetite and energy balance is genuinely still being worked out; the honest position is that researchers understand what tirzepatide does clinically better than they understand precisely why the addition of GIP activity helps.

In the United States, semaglutide is sold as Wegovy for chronic weight management and as Ozempic for type 2 diabetes. Tirzepatide is sold as Zepbound for weight management and Mounjaro for type 2 diabetes. The weight-management approvals apply to adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as type 2 diabetes, high blood pressure or obstructive sleep apnoea. Both are approved as an addition to changes in diet and physical activity, not instead of them — that phrasing is on the labels, and it reflects how the trials were run.

What the head-to-head evidence broadly indicates

For most of the time these drugs have existed, comparisons were indirect: people lined up results from separate trials with different populations and different protocols, which is a poor way to compare anything. A direct comparison in people with obesity has since been done, and it pointed the same way the indirect comparisons did — tirzepatide produced greater average weight loss than semaglutide over the study period, with both producing substantially more than placebo.

Three caveats belong immediately next to that sentence.

First, an average is a summary of a distribution. In every trial in this class there are people who respond strongly, people who respond modestly, and people who barely respond at all. Knowing which group you fall into is not possible in advance, and no clinician should tell you otherwise.

Second, more weight loss is not automatically the better clinical outcome for a given person. If someone cannot tolerate the drug that produces more weight loss on average, it produces none for them. Adherence is the variable that quietly decides most of this.

Third, the two drugs have different accumulated evidence beyond weight. Semaglutide has been studied for cardiovascular outcomes in people with established cardiovascular disease and overweight or obesity, and carries an approval reflecting that. Tirzepatide carries an approval for moderate-to-severe obstructive sleep apnoea in adults with obesity. If either of those applies to you, it may matter more than the difference in average weight change.

Tolerability

Both drugs produce gastrointestinal side effects in a substantial proportion of people, particularly early on and after each dose increase. Nausea is the most common, followed by constipation, diarrhoea, vomiting and reflux. In most people these are worst in the days after a dose change and settle as the body adapts. In a minority they do not settle, and that is a legitimate reason to change drug, hold at a lower dose, or stop.

Anecdotally, some people tolerate one of these drugs and not the other, and switching is a normal clinical move rather than an admission of failure. There is no reliable way to predict who that will be. We cover what to expect and what actually helps in our guide to GLP-1 side effects, including the small set of symptoms that mean you should stop waiting it out and contact someone.

The titration schedule and why it is not negotiable

Both drugs start at a dose that is not expected to do much. Semaglutide for weight management begins well below its maintenance dose and steps up at roughly four-week intervals. Tirzepatide begins at its lowest strength and steps up on a similar schedule toward one of several maintenance doses. The escalation is slow because gastrointestinal tolerance improves with time at a given dose, and rushing it reliably produces more nausea and more people abandoning treatment.

This has a practical consequence people find frustrating: the first month or two is largely about getting to a dose that does something. It is also a reason to be suspicious of any provider willing to start you high, or to escalate faster than the labelled schedule, because the only thing that buys is side effects.

It is worth saying plainly that the maximum dose is not the goal. Some people do well and stay at an intermediate dose indefinitely. Escalating simply because a higher number exists is not good practice.

Cost, coverage and supply

For a great many people this is the actual deciding factor, and pretending otherwise is not useful. Coverage for weight-management indications varies enormously between insurers and employers, and a plan that covers one of these drugs may not cover the other. Manufacturer savings programmes exist, change frequently, and usually depend on your insurance status. Both manufacturers have at points offered lower-cost self-pay routes for certain doses.

Supply has also been a real constraint. Both drugs spent time on the FDA's drug shortage list, and those shortages are what opened the door to widespread compounding of semaglutide and tirzepatide. That situation has since changed, and it changed the legal position of compounded products substantially. If you are considering a compounded preparation because of price, read what to understand about compounded GLP-1s first — compounded semaglutide and tirzepatide are not FDA-approved products, and the difference is not a technicality.

Choosing between them

A reasonable clinician weighs, roughly in this order: what your history rules out, what your insurance will actually cover, what other conditions you have that one drug addresses and the other does not, and how you tolerate what you start on. The trial data informs the conversation. It rarely settles it on its own.

Some things that genuinely change the answer: a personal or family history of medullary thyroid carcinoma or MEN2 rules out both. A history of pancreatitis, significant gastrointestinal disease, pregnancy or plans for pregnancy, or an active eating disorder all warrant careful discussion and may rule out treatment entirely. Our article on who should not take a GLP-1 goes through that list properly. A clinician may well conclude that neither drug is appropriate for you, and that conclusion is a clinical judgement rather than an obstacle to be shopped around.

What neither drug does

Neither medication removes the need for the rest of it. Protein intake, resistance training, sleep and alcohol all still affect what happens to your body composition and how durable any change is — not as an optional add-on, but as part of the treatment. Rapid weight loss costs lean mass alongside fat, which is covered in our article on muscle loss during GLP-1 treatment.

And neither is a short course. Obesity behaves as a chronic condition, and both drugs behave like treatments for one: their effect depends on continuing to take them. That has implications worth understanding before you start rather than after.

If you want to talk through which, if either, fits your history, our weight management service exists for that conversation, and you can book a consultation with a licensed clinician. Nobody can tell you which drug is right for you from an article.